FABP4, fatty acid binding protein 4, 2167

N. diseases: 194; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.070 Biomarker disease BEFREE A-FABP and oestrogens are independently involved in the development of breast cancer. 31755351 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.070 AlteredExpression disease BEFREE It can therefore be concluded that the expression of FABP4 might have a prognostic value in patients with BC. 30694572 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.070 Biomarker disease BEFREE Fatty acid-binding protein 5 was positively associated with BMI, FABP4, VLDLc, triglycerides, glycerol, and hsCRP (<i>p</i> < .05), and was negatively associated with HDLc and Apolipoprotein AI (ApoAI) (<i>p</i> < .05) in breast cancer patients. 28701570 2017
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.070 Biomarker disease BEFREE Moreover, eFABP4 enhanced the proliferation of these breast cancer cells but did not have any effect on MCF-7 and MDA-MB-231 cell migration. 27061264 2017
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.070 Biomarker disease BEFREE To better understand the role of AP2 factors in hormone responsive breast cancer, we sought to identify AP2-target genes in breast epithelial cells. 17187826 2007
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.070 AlteredExpression disease BEFREE These results uncover that unusual stability is the main mechanism that raises the levels of AP-2 proteins, and in addition, provide the first clue that defective ubiquitin-dependent proteasomal-degradation pathway is possibly the prime cause that affects the HER-2/neu gene and culminates in breast cancer. 16108032 2006
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.070 AlteredExpression disease BEFREE The AP-2 genes are expressed in many human breast cancer cell lines, and critical AP-2-binding sites are present in both the ERBB-2 (HER2/neu) and estrogen receptor promoters. 9850080 1998